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Eastern Indiaexplored in the Eastern Indian population with low HCC incidence. DNase I
sensitive HBV DNA was detected in 53% samples, which differed signiﬁcantly between clinical groups
(Pb0.001). HBV genotypes A (Aa/A1), C (Cs/C1) and D (D1, D2, D3, D5) were detected in 37.5%, 18.7% and
43.7% samples respectively. Population speciﬁc signature HBx residues A36, V88, S101 in Aa/A1 and residues
P41, Q110 in D5 were detected. Mutations T127, M130 and I131 were detected in 66.7%, 91% and 75% of genotype
A, C and D5 samples respectively. Very low occurrence of HCC associated mutations (V5M/L, P38S, and H94Y)
and absence of C-terminal deletions were observed. Our study shows that HBV genotype associated clinically
important HBx variations may evolve and act distinctly in different geo-ethnic populations. Further studies
on HBx functions from the perspective of genetic variability are essential for the better understanding of the
clinical signiﬁcance of HBV.
© 2008 Elsevier Inc. All rights reserved.IntroductionHepatitis B virus (HBV) infection is a global health problem with
more than 2 billion infected individuals. HBV infection leads to diverse
outcomes ranging from acute to fatal fulminant hepatitis, and chronic
hepatitis (CHB), which may result in severe complications as liver
cirrhosis (LC) and hepatocellular carcinoma (HCC). Hepatitis B virus
(HBV) is one of the important human DNA viruses having strong
oncogenic potential (De Oliveira, 2007).
Genetic and phylogenetic analysis of HBV DNA sequences has lead
to the deﬁnition of eight genotypes designated A through H, based on
more than an 8% diversity in the whole genome, and further into their
subgenotypes (more than 4%, but less than 8% intragenotype
diversity), having distinct ethno-geographical distribution (Schaefer,
2005). Recent studies have clearly demonstrated that genotype
variability of different HBV genetic regions can inﬂuence the clinical
manifestation, and even response to therapy (Schaefer, 2005).).
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(PreS/S, PreC/C, Pol and X). Considering their clinical signiﬁcance in
diagnostics, immune evasion, vaccine development, immune activa-
tion functions and drug resistance, studies on the genetic variability of
the PreS/S, PreC/C and Pol genetic regions have remained at the foci of
earlier investigation. However, data on the clinical impact of HBx
genetic variability is still sparse (Kim et al., 2008). The X ORF is the
smallest, but expresses a 154 amino acid multifunctional molecule
(HBx), with an N-terminal negative regulatory/antiapoptotic and a C-
terminal proapoptotic/transactivation domain, and has widely been
associated with modulation of a wide range of normal cell functions,
leading to HCC (Bouchard and Schneider, 2004; Schuster et al., 2002;
Tang et al., 2006). In view of its strong involvement in HBV related
pathogenesis, recent genetic analysis studies from our group and
others (Datta et al., 2007; Sung et al., 2008), and in vitro functional
analysis studies (Lin et al., 2005; Tan and Chen, 2005) have highlighted
the clinical substance of HBx genetic variability. We have earlier
demonstrated that HBx genetic variability can enlighten the differ-
ential oncogenic potential of HBV genotypes (Datta et al., 2007).
In India, more than 10% of the global chronic HBV population reside
(Sarin et al., 2001). HBV genotypes A and D are known to circulate in
different parts of India (Thakur et al., 2002; Gandhe et al., 2003;
Vivekanandan et al., 2004). In addition to these two genotypes, we
have recently documented, characterized and found that HBV
Fig. 1. Figure showing the percentages of X gene ampliﬁcation among a total of 102 HBV
Surface gene PCR positive samples, belonging to different clinical groups. The number of
samples in each clinical group is shown in the parentheses below the bars.
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remained conﬁned in the Eastern India population (Datta et al., 2006;
Banerjee et al., 2006a, 2006b). Based on full-length genome analysis,
we have also revealed that HBV genotypes A and C circulating in the
eastern part of India are phylogenetically related to HBV strains
prevalent in Sub-Saharan Africa and East Asia respectively (Banerjee
et al., 2006a). Interestingly, despite this similarity in circulation of HBV
genotypes, the incidence of HCC is very low in India (average annual
incidence of ≤3.3 HCC cases/100,000 individuals), compared to Sub-
Saharan Africa and East Asian countries (average annual incidence of
≤98.9 HCC cases/100,000 individuals) (Hussain et al., 2007). Regard-
less of such an interesting facet of HBV epidemiology, the clinical
relevance of the HBx genetic variability of Indian HBV strains has not
been sought previously.
The main aim of this study was to investigate the genetic
heterogeneity of HBx sequences in our population. We analyzed and
compared the HBx sequence from our study population with related
GenBank sequences andpublished literature related to clinically relevant
HBx variations. In this manuscript we discuss the clinical signiﬁcance of
the genetic variability of HBx andalso present theHBx genetic variability
in our study population with interesting HBV epidemiology.
Results
Ampliﬁcation of X gene
During this study, we observed a discrepancy in ampliﬁcation
results of the surface gene and the X gene region ampliﬁcation PCR
assays, although these assays had similar sensitivity, as calibratedwith
an international HBV DNA standard (NIBSC code 97/750; National
Institute of Biological Standards and Control, Hertfordshire, UK). Of
the 102 HBV DNA samples that were positive by partial surface gene
PCR (amplifying nts 184 to 731 from the EcoRI site), the HBV genome
region corresponding to nts 1092 to 1972 including the entire X gene
region could be ampliﬁed from a total of only 48 (47%) samples,
suggesting the absence of this region in the rest of the samples.
Among the rest of the 54 samples in which full-length X gene could
not be ampliﬁed, our attempts of amplifying partial X gene using
previously published primers also failed repeatedly. However the
extracts were repeatedly found to be positive for PCR assays
amplifying different regions of human genomic DNA and HBV core
gene/preC and PreS/S regions, ruling out the possibility of faulty DNA
extraction in these samples. Further, false positivity in the surface
gene, precore/core gene PCR due to cross contamination was also
excluded by the results obtained with controls included during
extraction and ampliﬁcation stages.
Fascinatingly, we observed that full-length X gene could only be
ampliﬁed in the extracts that had full-length DNase I resistant virionHBV DNA. Such intact virion HBV DNA was detected in a lower but
almost similar percentage of the acute hepatitis B (ACU), inactive
carriers (IC) and LC patients (37.5%, 34.4% and 33.3% respectively),
while the percentage of detection of intact viral genome was
signiﬁcantly higher (Pb0.001) in CHB and HCC patients (68.7% and
66.6% respectively) (Fig. 1). In the rest of the extracts, the dominant
proportion of HBV DNA was found to be defective HBV DNA, lacking
detectable HBx genetic region.
Phylogenetic analysis, genotypes and subgenotypes
The phylogenetic analysis (Fig. 2) of the 48 X gene sequences along
with GenBank reference sequences showed seven distinct clusters
corresponding to the HBV genotypes (A–D and F–H), however
genotype E, clustered with the genotype D sequences. Among the 48
sequences generated in this study, genotype D (43.7%) was most
frequently detected followed by genotype A (37.5%) and genotype C
(18.7%). The genotypes determined with HBx sequences in this study
matched exactly with RFLP patterns obtainedwith surface gene region
sequences (data not shown). No recombinants were observed in this
study. Among the isolates from the present study, all the 18 genotype
A isolates clustered with reference subgenotype Aa/A1 clade, all the 9
genotype C isolates clustered with subgenotype Cs/C1 clade. However,
21 genotype D isolates showed the most diverse topology, clustering
with clade corresponding to subgenotypes D1 (4 isolates), D2 (3
isolates), D3 (10 isolates) and D5 (4 isolates) (Fig. 2).
Inter-genotypic and inter-subgenotypic divergence
The phylogenetic clusters observed with the X gene region in this
study exactly matched with previously described genotype/subgeno-
type clusters obtained with whole genome sequences (Norder et al.,
2004). This suggested a high inter- and intra-genotypic variation in
the 465 nt encoding the X gene region, comparable to that in the full
genome of HBV. The mean inter-genotypic distances at the nucleotide
level and amino acid level are shown in Table 1. The mean inter-
subgenotypic distance among the subgenotypes of genotype A, B, C, D
and F in the full-length X gene, and its two distinct functional domains
(N-terminal and C-terminal) are shown in the Table 2. Comparison of
the consensus of reference subgenotype sequences showed a high
divergence at both the nucleotide and amino acid level, inter-
genotypically and inter-subgenotypically. However the N-terminal
showed an exceptionally high sequence divergence, compared to the
C-terminal, indicating an exceptionally high type speciﬁc variability in
the N-terminal domain.
Genotype speciﬁc residues
Comparison of the consensus sequences, calculation of dN and dS
at each codon position indicated the amino acid positions that were
signiﬁcantly different among the consensus sequences, representing
genotype speciﬁc residues (Fig. 3). These predicted sites were further
conﬁrmed by manually comparing with the reference sequence from
different countries, retrieved from the GenBank. As expected from the
divergence data, most of the speciﬁc residues were located in the N-
terminal (ﬁrst 50 amino acids) compared to the C-terminal regions.
Among the variable positions in the N-terminal domain, residues at 6,
12, 26, 30, 38, 40, and 42 were found to specify the genotypes and the
rest of the positions were well conserved within subgenotype
reference sequences. At the C-terminal, residues at 78, 91, 101, 102,
118 and 119 were shown to be genotype dependent (Fig. 3).
Genetic variability in the present sequences
Among the 48 HBx sequences generated in the present study, the
mean similarity between the sequences (in percentage) at nucleotide
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Table 1
Mean inter-genotypic divergence among the 8 HBV genotypes
Inter-genotype divergence (%)
A B C D E F G H
A nt 0.00
aa 0.00
B nt 7.40 0.00
aa 13.70 0.00
C nt 6.60 5.60 0.00
aa 10.90 8.50 0.00
D nt 5.50 6.50 8.00 0.00
aa 8.90 9.80 5.20 0.00
E nt 6.70 7.10 4.60 3.50 0.00
aa 11.10 11.10 7.80 5.90 0.00
F nt 11.00 10.80 10.60 10.80 10.60 0.00
aa 20.20 16.90 17.60 17.60 16.90 0.00
G nt 14.90 14.20 14.90 14.00 14.20 15.10 0.00
aa 22.80 18.90 21.50 20.80 20.20 22.10 0.00
H nt 12.10 10.60 10.40 10.80 10.40 8.00 15.70 0.00
aa 22.80 16.90 17.60 18.90 16.90 12.40 26.00 0.00
The numbers indicate percentage differences in the nucleotide (nt, shown in bold) and
deduced amino acid sequences (aa, shown in italics) of HBx.
Table 2
Mean inter-subgenotypic divergence among the 5 HBV genotypes, for which
subgenotypes have been classiﬁed
Length Inter-subgenotype divergence (%)
A (A1–A3) B (B1–B5) C (C1–C5) D (D1–D5) F (F1,F2)
Full X ORF 465 nt 1.8 1.7 3.6 2.1 2.0
154 aa 2.8 2.9 5.1 3.2 3.6
N-terminal 150 nt 3.4 2.2 4.7 3.0 2.3
50 aa 6.7 5.1 9.0 6.2 7.0
C-terminal 312 nt 1.0 1.5 3.2 1.6 1.9
104 aa 0.9 1.8 3.3 1.7 2.1
The numbers indicate percentage differences in the nucleotide (nt) and deduced amino
acid sequences (aa) of full X ORF, the N-terminal and the C-terminal domains.
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percentage) at amino acid level was 92.92±0.033.
Compared to the respective reference genotype consensus
sequence, the variability in the sequences generated in the present
study was determined. Sporadic mutations were observed at some
sites, although in the majority, the sequences were similar to the
consensus reference sequences, indicating low genetic variability in
these samples. However region speciﬁc variability (substitution at a
particular site in 50% or more of the isolates, compared to the
corresponding consensus reference sequence) was observed in
subgenotypes Aa/A1 (at positions 36, 88, 101), in Cs (at position 30),
in D1 (in position at 47) and in D5 (at positions 41, 102 and 110)
(Supplementary data 1). Compared to reference sequences, residues at
36, 88, 101 in Aa/A1 and residues 41, 110 in D5 were found to be
speciﬁc signature residues (prevalence N70%) in HBV strains circulat-
ing in our population.
For documenting the clinically relevant mutations, changes at
residue positions, other than the genotype speciﬁc sites were
documented (Supplementary data 2). A total of 29 residue positions
were found to have different substitutions in different clinical
categories. However, no speciﬁc substitutions corresponding to any
particular clinical outcomes were documented. Leucine (L) at HBx
residue position 5 was found in all our sequences. Residue A31 was
detected in all but one subgenotype Aa/A1 sequences. Residue S38 was
detected in only 2 subgenotype Cs/C1 samples. Substitution Y94 was
detected in 2 samples, one each of subgenotype Cs/C1 and D5. Residue
P101 was detected in 4 samples only from subgenotype Aa/A1.
Interestingly, substitution at position 127, 130 and 131 was present
in all the clinical categories. However, the occurrence of these
mutations were higher in genotypes A (66.7%), C (91%) and
subgenotype D5 (75%). Notably, in all but one case, mutation at
position 127 was always present with M130 and I131. Compared to IC
group, prevalence of M130 and I131 was signiﬁcantly higher among CHB
patients (36% vs. 55%, P=0.010) and HCC patients (36% vs. 100%,
Pb0.001). No insertions or deletions were observed, although a
premature stop codon appeared at position 104 in only one
subgenotype Cs/C1 isolate, predicting deletion of 50 C-terminal
amino acids.Fig. 2. Phylogenetic relatedness of the full-length X gene (465 nucleotides corresponding to p
Indian patients (taxa name starting with ‘EI’ or ‘EIX’, markedwith grey solid rounds), with refe
GenBank. Reference sequences are denoted by accession numbers and the country of origin. R
at a minimum for clarity of the ﬁgure. Genotypes, subgenotypes and bootstrap values are mPredicted characteristics of HBx protein
The PROSITE motif search program identiﬁed Protein kinase C
(PKC) phosphorylation site at positions 11, 54, 75 and Casein kinase II
(CK II) phosphorylation site at positions 11, 104. Interestingly, the PKC
and CK II phosphorylation sites in the HBx C-terminal (at sites 54, 75
and 104) are well conserved among all the genotypes. One PKC site
(S11SR) in the N-terminal was present only in Aa/A1 and Ac/A3, while
subgenotype Ae/2 had P11SR. The rest of the other genotypes had
either P11TR or P11AR.
The HBx protein was predicted to be a compact globular domain
(with 91 residues predicted to be exposed) by the GLOBE program. The
results of the prediction of helix, extended sheet and coiled loop by
PHD and PROF programs are presented in Supplementary data 3. The
random coiled structure was observed in the N-terminal region
corresponding to the hypervariable region, while the helical structure
was predicted in the C-terminal binding domains. Relative solvent
accessibility (in 10 states) as predicted by PROFacc was found to be
higher in residues corresponding to the hypervariable region of the N-
terminal.
Discussion
Using an advanced algorithm for protein structure prediction, in
contrast to a previous study (Colgrove et al., 1989), we in this study
detected non-alpha, non-sheeted, coiled-coil structure with relatively
high solvent accessibility of the N-terminal residues, suggesting a
dominant B-cell epitope region (Park et al., 2000). Further analysis of
the sequences of different HBV genotypes also showed thatmost of the
type speciﬁc variability is concentrated in the N-terminal of the HBx.
The presence of HBx genotype variability in the immunodominant
region supports the role of immune selection in evolution of different
HBV genotypes (Osiowy, 2006). It is well known that the N-terminal
domain of HBx is indispensable for dimerization, transforming activity,
anchorage-independent proliferation activity, negative regulation of
proapoptotic activity and can overcome oncogene induced senescence
(OIS) (Bouchard and Schneider, 2004; Tang et al., 2006). On the other
hand, due to the overlap with several regulatory elements (Tang et al.,
2006), the C-terminal domain of HBx sequence and its functions are
relatively well conserved (Schuster et al., 2002). Taken together, it is
evident from the present analysis that the HBxN-terminal domain and
its variability is involved in signiﬁcantly contributing to differential
pathogenic potentials of HBV genotypes/subgenotypes, which clearly
supports a recent study showing that effects of the same C-terminal
HBx mutations are genotype differentiated (Lin et al., 2005).
The present study reveals important facets of HBV genetic
variability in our study population. The detection of DNase I sensitiveositions 1374 to 1838 from the unique EcoRI site) sequences of HBV isolates from Eastern
rence sequences representing different genotypes and subgenotypes retrieved from the
eference sequences of genotypes (B, E, F, G, H) not detected in this part of Indiawere kept
arked at the nodes.
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Table 3
List of HBx residues/substitutions, previously shown to be relevant in HBx mediated
pathogenesis
Nucleotide
position
(s)a
HBx
residue
(s)b
Reported effects of the HBx
residues and/or corresponding
nucleotides
Genotype/subgenotype
speciﬁcity
1386C/A L/M5 Suggested to be a major target
of host immune response
against HBx and also affects
regulatory functions of HBV.
Signiﬁcantly associated with
HCC in Korean patients (Kim et
al., 2008).
cL5 — genotypes E, G, H, all the
subgenotypes of A, B, D, and
subgenotypes Cs/C1, C3, C4, C5,
F1
cV5 — subgenotype Ce/C2
cM5 — subgenotype F2
1467A A31 Low gene expression, escape
from immune surveillance,
reduced apoptosis, promotion
of HCC (Yeh et al., 2000).
cA31 — subgenotype Aa/A1
cP31 — genotype B, G, F2
dS31 — Genotypes C, D, E, H and
subgenotypes Ae/A2, Ac/A3,F1
1485T S38 Independent risk factor for
development of HCC in
genotype C (Muroyama et al.,
2006).
dS38 — all subgenotypes of A, D,
E, F1, G
cP38 — all subgenotypes of B, C,
F2, H
1497C P42 Phosphorylation of the motif
(S41P42) determines the
subcellular HBx location, p21
repression, leading to HCC
(Noh et al., 2004), and also
interacts with Pin1, leading to
HCC (Pang et al., 2007).
cP42 — all subgenotypes of A, B,
D, E, F, G, H, C5
dS42 — Cs/C1, Ce/C2, C3, (Datta
et al., 2007).
cA42 — C4
1653T Y94 1653T changes the α box
binding site that enhances the
binding afﬁnity and activity of
the enh II and core Promoter
(Shinkai et al. 2007), leading to
HCC.
dH94→ cY94 — HBx with H94
inhibit clonal outgrowth of
cells and induce apoptosis,
while with Y94 did not (Poussin
et al., 1999).
cY94 — genotype G
1674T S101 High expression of p21,
reduction of cell cycle and
increased apoptosis (Kwun and
Jang, 2004).
dS101 — B1–4, C, D, E, F, H
cP101 — all subgenotypes of A
cL101 — B5
1674C P101 Low expression of p21, increase
in cell cycle and thus cell
proliferation (Kwun and Jang,
2004).
cF101 — G
1762T M130 Strong inhibitor of p21,
increased cell proliferation
(Kwun and Jang, 2004). 1762T
prevent binding of LEFe,
suppress only preC mRNA
(HBeAg expression), enhance
progeny virus synthesis
(Kramvis and Kew, 1999).
dK130 → cM130
a mutation frequent in HCC
patients, infected with
genotypes A and C (Kramvis
and Kew, 1999).
1753C T127 These residues affect anti-
proliferative activity (Lin et al.,
2005). The nucleotides
enhance viral replication due
to a change in pgRNA stem loop
structure. The contribution of
mutation at 1764A is low
compared to 1762T (Kramvis
and Kew, 1999).
cI127 → dT127
1762T M130 dK130 → cM130
1764A I131 cV131 → cI131
Increases the anti-proliferative
activity of HBx of genotype B,
but not in genotype C (Lin et al.,
2005).
The genotype/subgenotype speciﬁcity of these mutations is also presented.
a Numbers and superscripted alphabets indicate nucleotide positions and bases
respectively.
b Alphabets and subscripted numbers indicate amino acid residues and their
positions respectively.
c Hydrophobic residue.
d Hydrophilic residue.
e Liver enriched factors.
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(Cabrerizo et al., 1997). Moreover, similar to the reports of the frequent
loss of surface and polymerase genetic regions of HBV in other
populations (Gunther et al., 1997), the frequent loss of HBx genetic
region appears to be a unique feature of HBV strains circulating in our
population. The phenomenon of the detection of HBV genome lacking
important HBV genetic regions has been suggested to occur due to
splicing (Gunther et al., 1997; Lee et al., 2008) or due to the circulation
of HBV DNA integrated in human chromosomes (Fleischhacker and
Schmidt, 2007). Recent studies have established that the HBx C-
terminal domain exercises a proapoptotic activity to counter balance
the proliferative and transforming activities of the HBx N-terminal
domain (Tang et al., 2006), which explains the frequent development
of HCC in patients with truncation in the HBx C-terminal region (Tu et
al., 2001; Liu et al., 2008). On the other hand, the abundance of HBV
DNA, lacking the entire HBx genetic region in this population and
extremely low occurrence of solely C-terminal truncated HBV in our
patients well correlate with low incidence of HCC in our population.
Furthermore the higher prevalence of intact virion DNA, in CHB
patients in this study underscores the importance of intact HBx in
persistently inducing immune response leading to chronic liver injury
(Bouchard and Schneider, 2004; Tang et al., 2006). On the other hand,
the higher prevalence of LC patients with HBV variants in our study
clearly supports a recent ﬁnding that HBV variants with deletions are
important in the pathogenesis of cirrhosis (Marschenz et al., 2006).
Thus, in addition to supporting previous ﬁndings, our study also
discloses other interesting results, which encourages further
investigations.
In this study, we detected three distinct HBV genotypes (A, C and
D) from the phylogenetic analysis of the HBx gene sequences that
conﬁrmed our previous results (Banerjee et al., 2006a; Banerjee et al.,
2006b). The Eastern Indian population thus provides an opportunity
to compare between three distinct HBV genotypes. Although due to
the detection of a number of patients with defective HBV genome and
low occurrence of HCC, we could study the variability of the HBx in a
relatively small number of patients, but our analysis presents the very
ﬁrst picture of the HBx genetic variability patterns in a population of
the Indian subcontinent.
In order to verify the clinical relevance of the mutations
documented in this study, we collected the available literature
focused on the functional signiﬁcance of different HBx substitutions
and sought their associations with genotypes/subgenotypes of HBV
(Table 3). We noted that most of the HBx substitutions associated with
severe liver disease, studied until now are either genotype speciﬁc or
prevalent among certain genotypes only (Table 3) and involved a
change from a hydrophilic to hydrophobic residue or vice versa at a
particular site. This also suggests that a small number of substitutions
emerging at particular positions in particular HBV genotypes/
subgenotypes may alter the local conﬁguration of HBx, which might
lead to altered functional properties of HBx. Moreover, the review of
the literature on this particular aspect seem to indicate that clinically
relevant substitutions may emerge differently in distinct populations
even with the circulation of similar strains of HBV.
In a recent study on Korean patients (Kim et al., 2008), where
subgenotype Ce/C2 is prevalent, a particular mutationM/L5 was found
to be signiﬁcantly associated with HCC development. In our analysis
we observed that in HBx of subgenotype Ce/C2, the naturally
occurring residue is V5, while in most other genotypes the naturally
occurring residues are M/L5 (Table 3). Thus, in the Korean population,
the substitution of the normal V5 with M/L5 appears to increase the
risk for HCC development in subjects infected with Ce/C2. Similarly, inFig. 3. Different features of the HBx. (a) Two functional domains (N-terminal and C-termina
(KI) highly conserved regions. (b) Sequence diversity among different subgenotypes of HBV
subgenotype (†) speciﬁc sites. (d) Codon-wise rate of synonymous (dS, green bars) and non
at speciﬁc positions in the N-terminal domain. (e) Hydropathy plot showing altered hydra previous study on Taiwan (Yeh et al., 2000), the A31 mutation of HBx
was signiﬁcantly associated with HCC. Interestingly, we detected a
high prevalence of A31 in non-HCC patients in our study population.l), the Proline-Serine Rich (PSR) hypervariable region and the split Kunitz domain like
genotypes, corresponding to the functionally important regions. (c) Genotype (‡) and
-synonymous (dN, brown bars) substitutions, showing high inter-genotype variability
ophobicity and/or antigenicity at genotype/subgenotype speciﬁc positions.
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Moreover examination of genotype speciﬁc residues, as reported by
Kidd-Ljunggren et al. (1995), we found that all the HBx sequences
reported by Yeh et al. (2000) were of genotype A. Interestingly based
on the analysis of surface gene region, prevalence of genotypes B and C
in Taiwanese HCC patients (Kao, 2003), while detection of genotype A
speciﬁc HBx sequences by Yeh et al. (2000) seem to indicate that the
prevalent strains of HBV in Taiwan might possibly be B/A, C/A
recombinants, which might have higher oncogenic potentials. Thus
the HBx with a A31 substitution found in this study, is a part of the
natural variability of non-recombinant genotype Aa/A1 strains in our
population and was not associated with higher occurrence of HCC.
Recently, Muroyama et al. (2006) reported HBx substitution S38 in
genotype C to be signiﬁcantly associated with HCC patients. However
the association of S38 with HCC remains unclear as in another recent
study from the same country (Japan), such association with HCC was
not documented (Shinkai et al., 2007). Another residue, Y94, has been
shown to induce clonal outgrowth of cells and inhibit apoptosis
(Poussin et al., 1999). The prevalence of these residues (S38 and Y94)
was found to be very low in our study population. In addition, most of
the present sequences had S101, which induces high expression of p21
(Kwun and Jang, 2004), leading the reduced cell proliferation and
increased apoptosis of the HBV infected cells.
In this study apart from genotype/subgenotype speciﬁc substitu-
tions and some regional variability, the occurrence of sporadic
mutation was also low, and mutations, insertions or deletions speciﬁc
for any clinical outcomewere not observed, similar to previous reports
(Cabrerizo et al., 1998; Terada et al., 2001). However, in accordance
with published reports (Kim et al., 2008; Sung et al., 2008; Song et al.,
2005; Iavarone et al., 2003) we also detected substitutions at 127, 130
and 131 residue positions among all the three genotypes, with
signiﬁcantly higher percentage among advanced liver disease
patients, supporting the clinical importance of these mutations (Kim
et al., 2008). Although functional signiﬁcance of the double mutations
(M130 and I131) have been sought, the results are contradictory, with
one report suggesting increased p21 repression activity (Kwun and
Jang, 2004) while two others documenting no alteration in the
transactivation function (Tu et al., 2001; Minemura et al., 2005).
Notably, these three studies were performed with HBV sequences
isolated from patients from Korea (Kwun and Jang, 2004), Japan
(Minemura et al., 2005) and France/South Africa (Tu et al., 2001),
countries with different prevalence of HBV genotypes, indicating that
the divergence in results may be due to genotype differentiated effects
of these HBx mutations, clearly supporting a recent ﬁnding (Lin et al.,
2005). In our study, C-terminal truncation was predicted in only one
non-HCC case, while in none of the HCC cases. This is in contrast to a
recent study from China, reporting that HBx C-terminal deletions are
frequent in both tumor and non-tumor tissues (Liu et al., 2008). Taken
together, it is evident from the present study that the variety of
clinically relevant HBx mutation/deletion patterns may have their
own prevalence and behavior in different geo-ethnic populations and
the high incidence of HCC in certain populations may signify the
presence of other risk factors, such as ethnicity, high dietary Aﬂatoxin
B1 exposure etc.
Interestingly, molecular epidemiological studies have revealed that
high incidences of HBV related HCC development in Sub-Saharan
African or East Asian countries is strongly associated with codon 249
mutation of p53, known to be induced by HBx expression and high
dietary exposure to Aﬂatoxin B1 (AFB1) (Hussain et al., 2007; Madden
et al., 2002). We would like to mention here that in a study on p53
mutations (Datta et al., unpublished data), we could not detect the
codon 249 mutation of p53 in any of our study population, which
corroborate with a previous study (Katiyar et al., 2000) documenting
very low prevalence of this particular HCC associated mutation in
Northern Indian HCC patients, despite high Aspergillus contamina-
tion. Interestingly, among the daily Indian diets, turmeric (activeingredient ‘Curcumin’) is widely used (Sinha et al., 2003), that has
been shown to protects against AFB induced mutagenicity and
hepatocarcinogenesis (Soni et al., 1997). The preventive role of Indian
spices and food additives in the low incidence of HCC and other forms
of cancers thus needs further investigations.
In conclusion, compared to other regions of world with high HCC
prevalence, Indian HBV isolates have very low prevalence of HBx
mutations, absence of C-terminal deletions in HBx, and absence of p53
codon 249 mutations. Thus, our study shows that clinically important
HBx mutations may emerge speciﬁcally in different HBV genotypes/
subgenotypes that might modulate different pathogenic pathways
through complex interactions with different ethnic and environmen-
tal risk factors. Therefore the clinical signiﬁcance of HBV genotypes
and correspondingmutations in a given populationmay not be always
relevant to another population, even if the prevalent viral strains are
similar in both the population. Taken together, evaluation of HBx
functions from the perspective of genetic variability and geo-ethnic
factors are thus essential for a better understanding of HBV genotype–
phenotype relations. Further studies on HBx functions, from the
perspective of genetic variability may help identify HBV genotype
speciﬁc pathogenetic pathways, which are essential for the develop-
ment of HBV genotype speciﬁc therapeutics to efﬁciently reduce the
burden of HBV related liver complications.
Materials and methods
Study subjects
The present study was done on 102 sera from HBsAg positive, HBV
surface gene PCR or HBV core gene PCR positive subjects who
presented with different clinical manifestations. These patients were
referred to our unit from different liver clinics, for detailed HBV DNA
analysis. All the subjects were screened for HCV or HIV infection,
chronic alcoholism or other concomitant causes of liver diseases,
before including in the study. Of the sera included for X gene
ampliﬁcation, sequencing and analysis, 32 sera were from inactive
carriers (IC), 32 were from chronic Hepatitis B (CHB) and 24were from
liver cirrhosis (LC) patients. Due to low incidence in this region, we
could study sera from only 6 well diagnosed HCC cases. Sera from only
8 acute hepatitis B (ACU) patients, satisfying the study inclusion
criteria were available for detailed analysis.
This work was the part of a study approved by the institutional
Ethics Committee. Informed consentwas obtained from the subjects or
their guardians before blood collection.
Serological markers
Commercial ELISA based kits were used for HBsAg (Biomerieux,
Boxtel, The Netherlands), HBeAg/anti-HBe (Biomerieux, and EQUIPAR,
Soronno, Varese, Italy), anti-HCV (Ortho-Clinical Diagnostics, New
Jersey, USA) and anti-HIV (Biomerieux) detection. ALT was estimated
by Ecoline ALAT kit (Merck Specialties, Mumbai, India).
DNA extraction, ampliﬁcation and sequencing
HBV DNA was extracted from serum by Proteinase K–Phenol/
chloroform method. Ampliﬁcation of the partial promoter region of
the human interleukin-1β gene was done for veriﬁcation of the DNA
extraction procedure and HBV DNAwas initially detected by in-house
nested HBV surface or precore/core gene ampliﬁcation PCRs. Strict
precautions were followed to avoid cross contamination and appro-
priate negative and positive controls were included during DNA
extraction and PCR ampliﬁcation steps.
HBV X gene region was ampliﬁed by a hotstart PCR protocol
(AmpliTaq Gold DNA polymerase, Applied Biosystems, Foster City, CA,
USA), and the primers HBx1093F [5′-actttctcgccaacttacaaggccttt-3′
197S. Datta et al. / Virology 382 (2008) 190–198(1092–1118)] and HBx1977R [5′-gaaggaaagaagtcagaaggcaa-3′
(1972–1950)] for ﬁrst round ampliﬁcation, and primers HBx1265F
[5′-gccgatccatactgcggaactc-3′(1259–1280)] and HBx1887R [5′-
ccaaggcacagcttggaggct-3′(1885–1865)] for nested ampliﬁcation of
the full X genetic region. The primers were speciﬁcally designed to
anneal to highly conserved regions of the HBV genome. In addition to
these primer sets, previously published primers (Kidd-Ljunggren
et al., 1995) for the ampliﬁcation of partial X gene fragments were also
used, where full X gene ampliﬁcation could not be obtained by the
above mentioned PCR. PCR ampliﬁed products were puriﬁed (Qiagen
GmbH, Hilden, Germany) and directly sequenced using a Prism Big
Dye 3.0 Kit and ABI 3100 automated DNA sequencer (Applied
Biosystems, Foster City, CA, USA).
Detection of circulating virion free HBV DNA
Although all the sera samples included in this study had HBV
surface gene sequences ampliﬁable by nested PCR, HBV X gene
sequences could not be ampliﬁable in a number of these samples,
despite similar ampliﬁcation efﬁciencies of both the PCR assays. This
observation prompted us to probe for the presence of DNase I sensitive
HBV genomes in these cases. To distinguish between DNase I sensitive
HBV DNA and virions associated intact HBV DNA, 400 μl of sera
samples were divided into two parts. One part was digested with
DNase I (New England Biolabs, Beverly, USA) at 37 °C for 30 min
following an earlier described method (Cabrerizo et al., 1997). The
DNase I digested and undigested parts of each serum sample were
then subjected to DNA extraction, and ampliﬁcation by nested PCR
assays as described previously.
Molecular evolutionary analyses
All the HBx sequences generated in this study were edited
manually by visual inspection and were multiply aligned with
reference full genome HBV sequences (retrieved from the GenBank)
of different genotypes and subgenotypes (Norder et al., 2004), using
ClustalW program incorporated in Bioedit version 7.0 (Hall, 1999).
Genetic distances were estimated by Kimura's two-parameter
method and the phylogenetic tree was constructed by the
neighbor-joining (NJ) method. The reliability of the pairwise
comparison and phylogenetic tree analysis was assessed by boot-
strap resampling with 1000 replicates. Phylogenetic and molecular
evolutionary analyses were done using MEGA version 3.0 (Kumar
et al., 2004).
Consensus sequences, rate of non-synonymous (dN), synonymous (dS)
substitutions and signature amino acid patterns
To determine the consensus sequences, 114 full-length GenBank
sequences belonging to different HBV genotypes/subgenotypes, and
submitted from different countries were retrieved analyzed and used
for comparison of the sequences generated in the present study.
Consensus sequences of different genotypes were aligned, codon-wise
dN, dS were calculated and compared to determine the residues that
were signiﬁcantly different among genotypes. Codon-wise dN, dS
between the consensus sequences and signature amino acid patterns
were calculated using sequence analysis tools — CONSENSUS, SNAP
(Nei and Gojobori, 1986) and VESPA (Korber and Myers, 1992)
respectively, available at the Los Alamos National Laboratory website
(http://hcv.lanl.gov/).
Prediction of structural characteristics of HBx
To identify potential antigenic sites of HBx, hydrophobicity proﬁle
was created employing the Kyte and Doolittle (1982) method,
implemented in Bioedit version 7.0. Predictions of different structuralcharacteristics of HBx were done, utilizing the PredictProtein server
(Rost et al., 2004; http://www.predictprotein.org/).
Statistical comparisons
Statistical differences were calculated using the χ2 test or Fisher's
exact probability test and Student's t-test where applicable. Two
tailed P values≤0.05 were considered statistically signiﬁcant. For
statistical calculations, Microsoft Ofﬁce Excel (Microsoft Corporation,
USA) or StatCalc (EpiInfo, version 6.0, CDC, USA and WHO, Switzer-
land) were used.
GenBank accession numbers
The GenBank accession numbers of Eastern Indian HBV X gene
sequences analyzed in this study are EF594748 through EF594786 and
DQ315776 through DQ315786.
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